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Abstract
BACKGROUND: The risk of acute kidney injury in cystic fibrosis (CF) patients is due to renal tubular affection by 
CFTR gene.
AIM: Our study aimed at early detection of renal impairment in CF patients, to enable careful monitoring and 
adjustment of nephrotoxic medications.
METHODS: Fifty patients with CF were enrolled in our study; they were age- and sex-matched to 40 healthy control 
children. All subjects were screened by urine analysis, measurements of kidney function tests, fractional excretion of 
sodium, β2-microglobulin (beta-2-M) excretion, and renal ultrasound examination. Urinary kidney injury molecule-1 
(KIM-1) was assayed using ELISA technique.
RESULTS: Both urinary beta-2-M and KIM-1 concentrations were significantly higher in CF patients compared to the 
control group (p < 0.001). The duration of the disease was significantly positively correlated with the urinary beta-2-M 
and KIM-1 levels (r = 0.6 and 0.7, respectively; p < 0.01).
CONCLUSIONS: Our results showed that urinary KIM-1 can be considered as a sensitive early indicator of acute 
renal injury.
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Introduction
Cystic fibrosis (CF) is the most common 
lethal, autosomal, recessively transferred genetic 
disorder among Whites [1]. The CFTR gene encoding 
the CF transmembrane conductance regulator (CFTR) 
protein, spanning 1480 amino acids [2]. Epithelial cells 
of airways, the gastrointestinal tract (including the 
pancreas and biliary system), the sweat glands, and the 
genitourinary system mostly express CFTR gene [3]. 
CFTR gene dysfunction is the major cause of severe 
chronic lung disease in children, resulting in a wide and 
variable spectrum of manifestations and presenting 
complications [4]. Moreover, CF individuals are at risk 
of acute kidney injury (AKI) and the development of 
chronic renal disease, mainly due to exposure to multiple 
possibly nephrotoxic agents including aminoglycosides, 
nonsteroidal anti-inflammatory drugs, and immune 
suppressants. These factors contribute to the risk of AKI 
and ultimately the development of chronic renal disease 
[5]. A type-I transmembrane glycoprotein known as 
kidney injury molecule-1 (KIM-1) is primarily expressed 
on the surface of T-cells and possesses two extracellular 
domains [6]. Normal kidney shows low expression of KIM-
1, however, it is significantly increased following kidney 
injury in cells of proximal tubules. Following kidney injury, 
the extracellular domains of KIM-1 separate from the cell 
surface and pass through urine in a metalloproteinase-
dependent process [7]. Rapid increase in urinary KIM-1 
develops on tubular injury, the degree of injury, interstitial 
fibrosis, and inflammation which are all correlated 
with this increase. Investigation of kidney diseases is 
frequently performed through the assessment of serum 
creatinine and urinary albumin. Yet, these biomarkers 
are not sensitive enough for early detection of changes in 
renal function [8]. Urine β2-macroglobulin (β2M) values 
indicate renal filtration disorders. Measurement of values 
in both serum and urine can help distinguish a problem 
of cellular activation from a renal disorder [9]. Increased 
urine β2M levels reflect tubular disorders of the kidney. In 
such cases, serum β2M levels are usually normal since 
the dysfunction is in tubular reabsorption [10].
In view of these facts, there is a desperate need 
to identify the most appropriate way of measuring and 
monitoring renal function in these potentially vulnerable 
patients. Awareness of the importance of renal function 
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monitoring is vital as by the time the patients’ creatinine 
starts to increase they will have lost 50% of their renal 
function. With the modern advances in the diagnosis 
and management of CF patients and its impact on 
their survival for longer decades, it is imperious that 
we preserve their renal function, to maintain their aging 
years [11].
Based on the fact that CFTR is expressed in 
the renal tubules. We hypothesized in this work that 
there is some degree of renal impairment in young CF 
patients, even before exposure to provocation factors 
that will produce definite renal impairment later in 
life. Our aim was to detect early renal impairment in 
patients with CF through sensitive urinary biomarkers 
such as urinary KIM-1 and β2-microglobulin (beta-2-M). 
Thus, we can closely monitor those patients and pay 
much attention to the prescribed medication, especially 
those with nephrotoxic effects such as Garamycin and 
Amikacin which are commonly used.
Methods
Study design
The current study included 50 patients with 
CF. Patients were recruited over a period of 2 years 
from the pulmonology unit at the Children’s Hospital, 
Cairo University, Egypt. It is a tertiary referral teaching 
hospital serving a population of 20 million. The CF 
clinic follows up about 300 patients. The study protocol 
was approved by the Ethics Committee of the Faculty 
of Medicine, Cairo University, as to be in agreement 
to with Helsinki Declaration II, Finland; IRB approval 
number 02-25-2016. Informed consents were obtained 
from the legal guardians of all participating subjects.
Eligibility criteria
Children already diagnosed as CF patients 
based on symptoms, signs, and two positive sweat 
chloride tests ≥60 mmol/L (carried out at our hospital) 
as recommended by CF Foundation guidelines, using 
Wescor Macroduct system for collection of sweat 
by pilocarpine iontophoresis and then quantitative 
analysis by chloridometer in our laboratory [12]. Both 
genders were included with age ranges between 1 and 
15 years.
Exclusion criteria
Patients with one or more of the following were 
excluded from the study:
a. Receiving systemic or inhaled Garamycin or 
Amikacin
b. Those with CF-related diabetes
c. Those with congenital renal anomalies or 
family history of renal diseases (renal stones 
and inherited tubular diseases).
Control group
The included patients were age and sex matched 
to 40 healthy children recruited from the ophthalmology 
clinic or from the vaccination center as a control group 
to compare the values of the urinary biomarker used in 
the study between healthy children and children with CF.
Analytic approach
All the CF patients were subjected to full clinical 
history taking and thorough clinical examination. They 
were all subjected to laboratory assessment according 
to the following protocol:
1. Sampling
 Blood and morning mid-stream urine specimens 
were collected, aliquoted, and stored at -80°C 
till the time of the assay
2. Biochemical analysis of urine samples.
 Urinary KIM-1 and urinary beta-2-M were 
assayed using commercially available ELISA 
kits (Catalog No: DKM100 and Catalog 
No: EM5001-1, respectively), following the 
manufacturer’s instructions.
Renal imaging
The ultrasonic renal examination does 
not require any preparation of the patient and was 
performed with the patient in the supine position. The 
kidneys were examined in longitudinal and transverse 
scan planes with the transducer placed in the flanks. 
Patients were examined with a linear array transducer 
with higher center frequencies.
Statistical methods
Data were coded and entered using the statistical 
package SPSS version 22. Data were summarized using 
mean±standard deviation for quantitative variables and 
frequencies (percentages) for categorical variables. 
Comparisons between categories were made using 
unpaired t-test in normally distributed quantitative 
variables. Correlations between quantitative variables 
were carried out using Pearson’s correlation coefficient. 
p < 0.05 was considered as statistically significant.
Results
The mean age of the study population was 
4.65 years ranged between 1 and 11 years, whereas 
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the mean age at first presentation was 0.46 years 
ranged between 0.08 and 4 years. Twenty-nine patients 
(58%) were male and 21 (42%) were female, as shown 
in Table 1. Twenty-two patients (44%) were born from 
consanguineous marriage and 10 (25%) had sibling 
with CF in the same family. Baseline data of the studied 
population are illustrated in Table 1.
Table 2: Clinical manifestations among CF patients at the time 
of enrollment
Variable n=50*
Chronic cough 46 (92)
Pulmonary exacerbations 39 (78)
Clubbing 18 (45)
Pancreatic insufficiency 45 (90)
Distal intestinal obstruction 3 (6)
Liver affection 1 (2)
Failure to thrive 46 (92)
*Data are presented as frequency (%).
Regarding the clinical presentation of CF 
patients chronic cough was the main respiratory 
symptom (92%) and pulmonary exacerbations were 
present in most cases (78%) as the primary cause 
of attending the CF clinic. Pancreatic insufficiency 
(steatorrhea) is the main GIT symptom (90%). Failure to 
thrive, defined as weight and height below third centile, 
is present in most cases (92%) and only 1 patient (2%) 
had elevated liver enzymes, as shown in Table 2.
Renal imaging showed that 49 patients (98%) 
had normal renal U/S studies and one patient had 
Grade-1 nephropathy. Routine urine analysis was 
normal in 84% of the cases, while only 16% showed 
some albuminuria, oxaluria, and hyperuricosuria, as 
indicated in Figure 1. The mean values of beta-2-M and 
KIM-1 in cases and control group presented in Table 3 
were the results that showed significant increase of 
beta-2-M level in patients when compared to normal 
control with 36.75% and showed significant increase 
of KIM-1 level in patients when compared to normal 
control with 19.09% at p < 0.05.
Table 3: Urinary biomarker (β2MG and KIM‑1) values in 
patients and control children
Variable CF patients (n=50) Control (n=40) p-value
β2MG (ng/ml) 614.32 (40.08) 449.22 (46.33) <0.05
KIM-1(ng/ml) 0.57 (0.09) 0.307 (0.043) <0.001
Data are presented as mean (SD).
These results are illustrated in Figure 2, 
respectively. The duration of disease was positively 
correlated with both urinary biomarkers (beta-2-M and 
KIM-1) (r = 0.83 and 0.78, respectively, p < 0.01), as 
Figure 1: Urine analysis results among cystic fibrosis cases. Routine 
urine analysis was normal in 84% of the cases, while only 16% 
showed some albuminuria, oxaluria, and hyperuricosuria
presented in Figure 3. There was a non-significant 
correlation between both biomarker (beta-2-M and 
KIM-1) with fractional excretion of sodium (FENa), pH, 
bicarbonate, and sweat chloride testing at p > 0.05. 
There was a significant correlation between biomarker 
(beta-2-M and KIM-1) with the progression of age with p 
= 0.01, as presented in Table 4 and graphically illustrated 
in Figure 3. Beta-2-M and KIM-1 were positively 
correlated, r = 0.531, p = 0.01, as illustrated in Figure 4.
Figure  2:  Comparison  between  beta-2-M  and  KIM-1  proteins  in 
patients  and  controls.  (a)  Results  show  significant  increase  of 
beta-2-M    level  in  patients  when  compared  to  normal  control. 
(b) Significant  increase  in KIM-1  level  in patients when compared 
to normal control.
a
b
Table 1: Demographic data of CF patients
Variables n=50
Age in years 4.65 (2.82)*
Age of first presentation in years 0.46 (0.61)*
Sweat chloride testing 95.80 (29.12)*
Male 29 (58)#
Female 21 (42)#
Positive consanguinity 22 (44)#
Positive family history 12.5 (25)#
*Data are presented as mean (standard deviation). #Data are expressed as frequency (%).
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Discussion
Hypothesis regarding early renal impairment 
in young children with CF is based on the presence of 
CFTR in the renal tissue, as well as some few studies 
that searched for early renal involvement, urolithiasis, 
and estimated GFR in children with CF [13]. However, 
there are many factors affecting the renal function in 
CF due to increased life expectancy as well as the 
progression of the disease, recurrent infections, and 
subsequent use of potentially nephrotoxic antibiotics, 
and it is difficult to tell at a later stage the exact 
mechanism. Hence, we included young patients aged 1 
till 11 years and excluded those receiving gentamycin or 
any nephrotoxic medications and those with no family 
history of renal disease. To the best of our knowledge, 
this is the 1st time in literature to study these two non-
invasive urinary biomarkers (i.e., beta-2-M and KIM-1) 
in children with CF, which surprisingly were significantly 
high in CF patients compared to controls. All patients 
had normal serum Na, K, BUN, and creatinine level, 
signifying that creatinine is not a reliable early indicator 
during acute changes in kidney function, which goes in 
line with the study conducted by Boer et al., in 2010, 
showing that serum creatinine levels can vary greatly 
with personal factors such as age, gender, and muscle 
mass. Muscle metabolism, certain medications, and 
hydration status play a role in creatinine level. It will not 
become elevated obviously unless GFR has decreased 
by at least 50% below its normal values [14]. Eight 
patients (16%) had abnormal urine analysis, including 
Figure 4: Correlation between urinary kidney  injury molecule-1 and 
β2-microglobulin. This figure denotes a significant positive correlation 
between both markers, r = 0.531, p = 0.01
albuminuria, oxalate, and uric acid and 42 patients 
(84%) had normal urine analysis, which shows that 
urine analysis only is not a reliable indicator of early 
changes in kidney function, as shown in the study of 
Shemesh et al. who evaluated the AKI after receiving 
Table 4: Correlation studies for biomarker the assayed 
biomarkers (β2MG and KIM‑1)
Variable Beta-2-M (n=50) KIM-1 (n=50)
r p-value r p-value
Age 0.603 0.01 0.689 0.01
FENa 0.128 0.377 0.239 0.095
PH 0.161 0.264 ‒0.217 0.130
Bicarbonate 0.102 0.482 ‒0.066 0.651
Sweat chloride testing 0.72 0.618 0.05 0.970
Figure 3: Correlation studies. (a) The duration of disease was positively correlated β2-microglobulin (beta-2-M), (r = 0.83, p < 0.01). (b) The 
duration of disease was positively correlated kidney injury molecule-1 (KIM-1), (r = 0.78, p < 0.01). (c) Significant positive correlation between 
urinary beta-2-M elevation and age (r = 0.603, p = 0.01). (d) Significant positive correlation between urinary KIM-1 elevation and age (r = 0.689, 
p = 0.01)
a
c
b
d
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three doses of cisplatin which is known nephrotoxic drug 
and showed that urine analysis was insensitive as an 
early indicator of acute renal injury [15]. Renal imaging 
showed that 49 patients (98%) had normal renal U/S 
studies and one patient had Grade-1 nephropathy, 
which also showed that renal U/S is not a reliable early 
indicator during acute changes in kidney function. This 
finding is similar with the study of Biggi et al., 2006, who 
evaluated the ultrasound parameters in patients with 
urinary tract infection, which concluded that ultrasound 
cannot distinguish cystitis from pyelonephritis in those 
studied children nor it can identify children with renal 
damage [16]. Beta-2-M is a good biomarker used to 
assess the glomerular and tubular functions. High 
level of serum β2-M indicates glomerular malfunction, 
while elevated urinary β2M suggests proximal tubular 
dysfunction. Recently, measurement of urinary β2M 
has become a well-known method of tubular function 
assessment. Measurement of β2M in urine sediment 
is included in RenalVysion™ (Bostwick Laboratories, 
Uniondale, NY) as a biomarker to evaluate renal tubular 
function [17]. Our study showed significant elevation of 
urinary β2M levels in the diseased group compared to 
control group (p < 0.05), with an increase of 36.75% 
vis-à-vis control group.
KIM-1 is a Type-1 transmembrane protein 
that is not normally detected in the kidney tissue but is 
present at very high levels in the epithelial cells of the 
proximal tubule in human and rodent kidneys usually 
after ischemic or toxic injury. The KIM-1 ectodomain 
is stable in urine for long periods of time, it is easily 
detected in kidney as well as in urine after AKI [18]. 
Hereby, there was a significant elevation of urinary 
KIM-1 levels in diseased group compared to the control 
group, where p < 0.05, with an increase of 19.09%. The 
meta-analysis done by Shao et al., in 2014, detected 
that urinary KIM-1 was an accurate and reliable method 
of diagnosis in infants and children rather than in adults. 
They concluded that the comorbid conditions, such as 
hypertension, diabetes mellitus, and atherosclerosis, 
which are more common in adults may influence urinary 
KIM-1 concentrations in adults. Furthermore, it was 
noted that the urinary KIM-1 is fairly sensitive 74.0% 
and highly specific 86.0% in diagnosing AKI [19].
These data support our hypothesis that 
renal injury starts early in life of patients with CF. 
Furthermore, both urinary levels of beta- 2-M and 
KIM-1, have significant correlation with the duration 
of disease in CF children, p = 0.01; indicating that 
there is progression of renal disease in CF patients 
regardless of the use of nephrotoxic medications. 
When comparing both biomarker (beta-2-M and KIM-
1) with FENa, blood pH, and bicarbonate, there was 
no significant correlation between them. This also 
applies to the values of the sweat chloride testing. By 
correlating the two biomarkers (beta-2-M and KIM-1), 
there was a significant direct correlation (p = 0.01) 
between them, where r = 0.467.
Conclusions
Renal impairment among CF patients increases 
with age. Urinary KIM-1 and beta-2-M are good early 
indicators of renal impairment in CF patients. Further 
studies with a larger population with different ethnicity 
are needed to support our study regarding early renal 
impairment in patients with CF. Thus, close renal 
monitoring of those patients and avoidance of factors 
aggravating renal impairment such as nephrotoxic 
antibiotics and salt depletion in addition to proper diet 
control are recommended to keep good nutritional 
status and overall good health condition.
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